CMS finalizes decision to limit coverage for controversial Alzheimer's drug, related imaging

Retrieved on: 2022-04-08 15:24:24

Tags for this article:

Click the tags to see associated articles and topics

CMS finalizes decision to limit coverage for controversial Alzheimer's drug, related imaging. View article details on hiswai:

Excerpt

The determination also covers any future FDA-approved monoclonal antibodies directed against amyloid with an indication for use in treating ...

Article found on: www.radiologybusiness.com